PD-L1 expression in tumour and stroma did not differ between molecular BC subtypes, although triple-negative patients had significantly higher PD-L1 expression in tumours than non-triple-negative patients (median 15%, range 0–115% vs. median 0%, range 0–120%; P = 0.032). The gene discussed is CD274; the disease is breast cancer.